Nonsteroidal anti-inflammatory drug-induced reactions and desensitization

Journal of Asthma

Volumn 41, Issue 4, 2004, Pages 375-384

  Berges Gimeno, M Pilar ^a,c   Stevenson, Donald D ^b  

^a Hospital Sur   (Spain)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c Hospital Sur de Alcorcon   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FENOPROFEN; FENOPROFEN CALCIUM; FLURBIPROFEN; HISTAMINE; IBUPROFEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; INDOMETACIN; ISOENZYME; KETOPROFEN; KETOROLAC; KETOROLAC TROMETAMOL; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MECLOFENAMATE SODIUM; MECLOFENAMIC ACID; MEFENAMIC ACID; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SALSALATE; SULINDAC; TOLMETIN; UNINDEXED DRUG;

ALLERGIC PNEUMONITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIGEN RECOGNITION; ASEPTIC MENINGITIS; ASTHMA; BRONCHOSPASM; CLINICAL PROTOCOL; CLINICAL TRIAL; CROSS REACTION; DESENSITIZATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; EYE DISEASE; FLUSHING; GASTRITIS; HISTAMINE RELEASE; HUMAN; HYPOTENSION; INTERSTITIAL NEPHRITIS; LEUKOCYTOCLASTIC VASCULITIS; LIVER DISEASE; NOSE DISEASE; PATHOPHYSIOLOGY; PERENNIAL RHINITIS; PROSTAGLANDIN SYNTHESIS; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; SIDE EFFECT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; STOMACH PAIN; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

ANGIONEUROTIC EDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ASTHMA; CROSS REACTIONS; CYCLOOXYGENASE INHIBITORS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; RHINITIS; URTICARIA;

EID: 3242685155     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.1081/JAS-120037650     Document Type: Review

References (58)

1. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265:16737-16740.
2. Sousa A, Pfister R, Christie PE, Lane SJ, Nasser SM, Schmitz-Schumann M, Lee TH. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax 1997; 52:940-945.
3. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma & Immun 2001; 87:177-180.
4. Stevenson DD, Simon RA, Zuraw BA. Sensitivity to aspirin and nonsteroidal antiinflammatorys Drugs. In: Adkinson NF Jr, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simon FE eds. Middleton: Allergy: Principles and Practice. 6th ed. St. Louis: Mosby and Co, 2003:1695-1710.
5. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232-235.
6. Vane JR. The mode of action of aspirin and similar compounds. J Allergy Clin Immunol 1976; 58:691-712.
7. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975; 1:60-67.
8. Takimoto CH, Lynch D, Stulbarg MS. Pulmonary infiltrates associated with sulindac therapy. Chest 1990:230-234.
9. Quiralte J, Blanco C, Castillo R, Ortego N, Carrilo T. Anaphylactoid reactions due to NSAIDs: clinical and cross-reactivity studies. Ann Allergy Asthma & Immun 1997; 78:293-296.
10. Bigby M, Stern R. Cutaneous reactions to non-steroidal antiinflammatory drugs. J Am Acad Dermatol 1985; 12:866-876.
11. Berges Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma & Immun 2002; 89:474-478.
12. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin induced asthma. AIANE investigators. European network on aspirin-induced asthma. Eur Respir J 2000; 16:432-436.
13. Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin. J Allergy Clin Immunol 1983; 71:574-579.
14. Marquette CH, Saulnier F, Leroy O, Wallaert B, Chopin C, Demarcq JM, et al. Long-term prognosis for near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for near-fatal attack of asthma. Am Rev Respir Dis 1992; 146:76-81.
15. Czerniawska-Mysik G, Szczeklik A. Idiosyncrasy to pyrazolone drugs. Allergy 1981; 36:381-384.
16. Quiralte J, Blanco M, Castillo R, Ortega N, Carrillo T. Anaphylactoid reactions due to NSAIDs: clinical and cross-reactivity studies. Ann Allergy Asthma & Immun 1997; 78:293-296.
17. Vanselow NA, Smith JR. Bronchial asthma induced by indomethacin. Ann Intern Med 1967; 66:568-573.
18. Samter M, Beers R Jr. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68:975-983.
19. Mathison DA, Stevenson DD. Hypersensitivity to non-steroidal anti-inflammatory drugs: indications and methods for oral challenge. J Allergy Clin Immunol 1979; 64:669-674.
20. Mathison DA, Lumry WR, Stevenson DD. Aspirin in chronic urticaria and/or angioedema: studies of sensitivity and desensitization. J Allergy Clin Immunol 1982; 69:135.
21. Pleskow WW, Stevenson DD, Mathinson DA, Simon RA, Schatz M, Zeiger RS. Aspirin desensitization in aspirin sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol 1982; 69:11-19.
22. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to non-steroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol 1977; 60:276-284.
23. Settipane RA, Shrank PJ, Simon RA, Mathison DA, Christensen SC, Stevenson DD. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995; 96:480-485.
24. Stevenson DD, Hougham A, Shrank P, Goldlust B, Wilson R. Disalcid cross-sensitivity in aspirin sensitive asthamtics. J Allergy Clin Immunol 1990; 86:749-758.
25. Smith WL. Cyclooxygenase enzymes; a review. Adv Immunol 1996; 62:167-215.
26. Szczeklik A, Nizankowska E, Bochenek G, et al. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001; 31:219-225.
27. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin sensitive asthmatic patients. J Allergy Clin Immunol 2001; 108:47-51.
28. Martin-Garcia C, Hinojosa M, Berges P, et al. Safety of cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002; 121:1812-1817.
29. Yoshida S, Ischizati Y, Onuma K, Shoji T, Nakayawa H, Amayasu H. Selective cyclo-oxigenase 2 inhibitor in patients with aspirin-induced asthma. J Allergy Clin Immunol 2000; 106:1201-1202.
30. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 2002; 46:2201-2206.
31. Gylfors P, Bochenek G, Overholt J, Drupka D, et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective anlgesic drug celecoxib. J Allergy Clin Immunol 2003; 111:1116-1121.
32. Asero R. Tolerability of rofecoxib. Allergy 2001; 56:916-917.
33. Sanchez-Borges M, Capriles-Hulett A, Caballero F, Perz C. Tolerance to COX-2 inhibitors in patients with NSAID-induced urticaria/angioedema. Ann Allergy Asthma & Immun 2001; 87:201-204.
34. Berges-Gimeno MP, Camacho-Garrido E, Garcia-Rodriguez RM, Alfaya T, Martin-Garcia C, Hinojosa M. Rofecoxib: safe in NSAIDs intolerant patient. Allergy 2001; 56:1017-1018.
35. Garcia-Rodriguez R, Hinojosa M, Camacho E, Berges-Gimeno P, et al. Celecoxib: safe in NSAIDs intolerance. Allergy 2002; 57:1085-1086.
36. Pacor ML, DiLorenzo G, Biasi D, Barbagallo M, Corrocher R. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and or NSAIDs. Clin Exp Allergy 2002; 32:397-400.
37. Nettis E. Tolerability of rofecoxib in patients with cutaneous reactions to NSAIDs. Ann Allergy Asthma & Immun 2002; 88:331-334.
38. Quiralte J, Saenz de San B, Florido JJ. Safety of slective COX-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma & Immun 2002; 89:63-66.
39. Woessner KM, Simon RA, Stevenson DD. Monosodium glutamate (MSG) sensitivity in asthma. J. Allergy Clin Immunol 1999; 104:305-310.
40. Simon RA, Stevenson DD. Adverse reactions to food and drug additives. In: Middleton E Jr, Ellis EF, Yunginger JW, Reed CE, Adkinson NF Jr, Busse WW, eds. Allergy: Principles and Practice. St. Louis: Mosby, 1993:1687-1704.
41. Widal MF, Abrami P, Lermeyez J. Anaphylaxie et idiosyncrasie. Presse Med 1922; 30:189-192.
42. Zeiss CR, Lockey RF. Refractory period to aspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol 1976; 57:440-448.
43. Stevenson DD, Simon RA, Mathison DA. Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol 1980; 66:82-88.
44. Stevenson DD. Aspirin desensitization in patients with AERD. Clin Rev Allergy Immunol 2003; 24:159-167.
45. Szczeklik A, Gryglewski RJ, Nizankowska E. Asthma relieved by aspirin and by other cyclooxygenase inhibitors. Thorax 1978; 33:664-665.
46. Lockey RF. Aspirin-improved ASA triad. Hosp Pract 1978; 13:129-133.
47. Chiu JT. Improvement in aspirin-sensitive asthmatic subjects after rapid aspirin desensitization and aspirin maintenance (ADAM). J Allergy Clin Immunol 1983; 71:560-567.
48. Lumry WR, Curd JG, Zeiger RS, Pleskow WW, Stevenson DD. Aspirin-sensitive rhinosinusitis: the clinical syndrome and the effects of aspirin administration. J Allergy Clin Immunol 1983; 71:580-587.
49. Stevenson DD, Pleskow WW, Simon RA, Mathinson DA, et al. Aspirin sensitive rhinosinusitis-asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 1984; 73:500-507.
50. Naeije N, Bracamonte M, Michel O, Sergysels R, Duchateau J. Effects of chronic aspirin ingestion in aspirin-intolerant asthmatic patients. Ann Allergy Asthma & Immun 1984; 53:262-267.
51. Nelson RP, Stablein JJ, Lockey RF. Asthma improved by acetylsalicylic and other nonsteroidal anti-inflammatory agents. NER Allergy Proc 1986; 7:117-121.
52. Sweet JM, Stevenson DD, Mathinson DA, Simon RA. Long term effects of aspirin (ASA) desensitization treatmen for ASA sensitive rhinosinusitis/asthma. J Allergy Clin Immunol 1990; 85:59-65.
53. Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996; 98:751-758.
54. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111:180-186.
55. Kowalski ML, Grzelewska-Rzymowska I, Szmidt M, Rozniecki J. Clinical efficacy of aspirin in "desensitised" aspirin-sensitive asthmatics. Eur J Respir Dis 1986; 69:219-225.
56. Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma & Immun 2003; 90:338-341.
57. Mathison DA, Lumry WR, Stevenson DD, et al. Aspirin in chronic urticaria and/or angioedema: studies of sensitivity and desensitization. J Allergy Clin Immunol 1982; 69:135.
58. Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ. Rapid oral challenge-desensitization for patients with aspirin-related urticaria- angioedema. J Allergy Clin Immunol 2000; 105:997-1001.